- Home
- QS vs NAMS Comparison
QS vs NAMS Comparison
Compare QS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- NAMS
- Stock Information
- Founded
- QS 2010
- NAMS 2019
- Country
- QS United States
- NAMS Netherlands
- Employees
- QS N/A
- NAMS N/A
- Industry
- QS Auto Parts:O.E.M.
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- NAMS Health Care
- Exchange
- QS Nasdaq
- NAMS Nasdaq
- Market Cap
- QS 2.9B
- NAMS 2.7B
- IPO Year
- QS N/A
- NAMS N/A
- Fundamental
- Price
- QS $5.22
- NAMS $23.55
- Analyst Decision
- QS Hold
- NAMS Strong Buy
- Analyst Count
- QS 5
- NAMS 7
- Target Price
- QS $6.26
- NAMS $38.17
- AVG Volume (30 Days)
- QS 21.8M
- NAMS 581.4K
- Earning Date
- QS 02-12-2025
- NAMS 02-06-2025
- Dividend Yield
- QS N/A
- NAMS N/A
- EPS Growth
- QS N/A
- NAMS N/A
- EPS
- QS N/A
- NAMS N/A
- Revenue
- QS N/A
- NAMS $33,594,000.00
- Revenue This Year
- QS N/A
- NAMS $131.53
- Revenue Next Year
- QS N/A
- NAMS N/A
- P/E Ratio
- QS N/A
- NAMS N/A
- Revenue Growth
- QS N/A
- NAMS 78.77
- 52 Week Low
- QS $4.65
- NAMS $15.19
- 52 Week High
- QS $9.52
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- QS 46.45
- NAMS 44.17
- Support Level
- QS $5.16
- NAMS $22.53
- Resistance Level
- QS $5.77
- NAMS $26.71
- Average True Range (ATR)
- QS 0.48
- NAMS 0.97
- MACD
- QS -0.08
- NAMS -0.45
- Stochastic Oscillator
- QS 4.44
- NAMS 23.89
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed an anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.